Foundational to now be available upon physicians patient experiences Sequoia is an adenosine kinase 4 receptor (Akt) antagonist approved by the FDA for treatment of peripheral neuropathy. In peripheral neuropathy patients cannot control their pain-producing neurons. The physician developed a coffee-like adenosine kinase 4 receptor agonist that unblocks pain pathways and functionally reverses the neuropathic pain epidemic.
Prior research findings demonstrate the effectiveness of adenosine kinase 4 (Akt) antagonists in treatment of itch fever migraine and several neuropsychiatric disorders.